Kirkland Represents Patient Square Capital on Series B Financing for Kriya Therapeutics

Kirkland & Ellis advised Patient Square Capital, a dedicated health care investment firm, on its Series B investment in Kriya Therapeutics, Inc., a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. The $100 million financing round was led by Patient Square Capital and also included participation from new investors and existing institutional investors. The financing, which closed today, will support Kriya Therapeutic’s mission of transforming the design, development and manufacturing of gene therapies. 

Read the transaction press release  

The Kirkland team was led by corporate partner Michael Weisser and associate Carl Witkin, ESG & impact partner Alexandra Farmer, environmental transactions associate Donna Ni, and tax partner Mark Schwed and associate Dana Quinn.